New trial
Spotlight
Phase 1/2a trial of NTS071, a TP53 Y220C directed activator
- Trial ID
- NCT07060989 on ClinicalTrials.gov
- Cancer type
- Solid Tumor
- Stage of research
- First-in-human
- Location
- 2 Locations
- Published in
- New in Oncology - July 25, 2025
This Phase 1/2a study by Nutshell Therapeutics (Shanghai) Co., LTD. evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of NTS071 in adults with advanced solid tumors harboring a TP53 Y220C mutation using a single-arm design. NTS071 is a small molecule activator targeting TP53 Y220C, and the trial investigates whether reactivating mutant TP53 can improve outcomes in patients who have progressed on prior therapies.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings